By the ZIVOLABS Medical Team · Updated April 2026 · 7 min read

Most of the public conversation around GLP-1 medication — in India and globally — has centred on women. PCOD, postpartum weight, hormonal obesity. But men make up a significant proportion of people living with obesity and metabolic disease, and the data on GLP-1 medication in men is equally strong. In some respects, the results are even better.

This article covers what the evidence says about GLP-1 medication in men, whether it works differently, and why so few Indian men are currently accessing treatment that could significantly improve their health.

How common is obesity in Indian men?

More common than most people acknowledge. National health surveys show that approximately 20–25% of urban Indian men are overweight or obese by Indian BMI standards. In metro cities and among desk-based professionals, the prevalence is higher still.

Indian men also carry a disproportionate burden of abdominal obesity — excess fat specifically around the abdomen and visceral organs. This pattern of fat distribution is particularly dangerous metabolically, and it is driven by the same combination of insulin resistance and lifestyle factors that GLP-1 medication directly addresses.

Type 2 diabetes, hypertension, fatty liver disease, and sleep apnoea — all strongly linked to excess weight — affect Indian men at high rates. And yet men are considerably less likely than women to seek medical help for weight management. Cultural attitudes around body weight, masculinity, and healthcare-seeking behaviour mean many Indian men manage these conditions poorly for years before a health crisis forces intervention.

Does GLP-1 medication work the same way in men?

The mechanism is identical — semaglutide binds to GLP-1 receptors in the gut and brain, reduces appetite, slows gastric emptying, and improves insulin sensitivity regardless of sex. The biology does not differ between men and women at this fundamental level.

What does differ is the starting point and the outcome profile.

Men tend to have more absolute weight to lose. The average overweight Indian man presenting for weight management carries more total body weight than the average woman — which means the absolute weight loss in kilograms is often higher, even when the percentage is similar.

Men respond somewhat faster in the early months. Clinical trial data consistently shows that men lose weight slightly faster than women in the first 3–6 months on GLP-1 medication — not dramatically so, but measurably. This is likely explained by higher baseline metabolic rate, higher muscle mass (which burns more calories at rest), and lower hormonal complexity around weight regulation compared to women with PCOD or menopausal hormonal shifts.

The STEP 1 trial data: In the landmark STEP 1 trial, average weight loss across all participants was approximately 14.9% of body weight over 68 weeks. Male participants showed comparable or slightly higher weight loss than the trial average.

Visceral fat responds well. The abdominal fat that characterises male metabolic obesity — the "pot belly" profile common in Indian men from their 30s onwards — is visceral fat, stored around the organs. This type of fat is highly metabolically active and responds well to both caloric deficit and the specific insulin-sensitising effects of GLP-1 medication.

The metabolic conditions most common in Indian men — and how GLP-1 helps

Type 2 diabetes. India has over 100 million adults with Type 2 diabetes, and men are significantly represented. Semaglutide reduces HbA1c by 1–1.8 percentage points, produces clinically meaningful weight loss, and has proven cardiovascular protective effects — a combination no other single medication offers.

Non-alcoholic fatty liver disease (NAFLD). Fatty liver is extremely common in overweight Indian men, often asymptomatic for years before causing serious damage. GLP-1 medication reduces liver fat significantly — trials show meaningful reductions in liver fat content as early as 3–6 months into treatment. This effect is partly from weight loss and partly from the direct metabolic effects of GLP-1 on the liver.

Sleep apnoea. Excess weight — particularly around the neck and abdomen — is the primary driver of obstructive sleep apnoea in Indian men. Weight loss of 10–15% consistently reduces sleep apnoea severity and in some patients eliminates the need for CPAP therapy. This has significant effects on daytime energy, cardiovascular risk, and quality of life.

Hypertension. Blood pressure improves with weight loss — typically 1 mmHg per kilogram lost. Patients on semaglutide show clinically significant reductions in systolic blood pressure that sometimes allow medication reduction under doctor supervision.

Cardiovascular risk. The SUSTAIN-6 trial showed a 26% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death) in high-risk diabetic patients on semaglutide. For Indian men with the combination of abdominal obesity, diabetes, and hypertension — a profile extremely common in the 40–60 age group — this is a directly relevant finding.

Why Indian men are not accessing this treatment

Despite the strong clinical case, men make up a minority of patients currently accessing GLP-1 treatment for weight management in India. The barriers are familiar:

Stigma around weight and healthcare-seeking. Many Indian men do not categorise excess weight as a medical problem. It is normalised — particularly the gradual weight gain of the 30s and 40s — and seeking help for it feels uncomfortable. The concept of a medical consultation specifically for weight management is associated in many men's minds with weakness or vanity.

Misunderstanding of the treatment. Some men assume GLP-1 medication is "for women" because of its visibility in conversations around PCOD and hormonal weight gain. The medication has no hormonal mechanism — it works identically in men.

Not recognising the metabolic emergency. Indian men often dismiss their weight as irrelevant until a specific health crisis — a diabetes diagnosis, a hypertension reading that shocks them, an ECG result. By that point, the metabolic damage has accumulated for years. Treating the weight earlier prevents that progression.

The online consultation barrier is lower than in-person. Men are more likely to begin the process through a private, home-based online consultation than to walk into a weight loss clinic. ZIVOLABS is designed with this in mind.

What does treatment look like for a man?

The clinical process is identical regardless of sex. A health assessment, an online consultation with a metabolic doctor, confirmation of eligibility based on BMI and health profile, prescription, and monthly monitoring.

What may differ in the doctor's approach:

• Particular attention to testosterone levels, as obesity reduces testosterone in men and weight loss typically restores it

• Assessment of liver function (NAFLD is common and relevant to dosing considerations)

• Cardiovascular risk assessment — given that Indian men with obesity in the 40–60 age bracket often carry elevated cardiac risk

• Review of sleep quality — screening for sleep apnoea is relevant

• Assessment of existing diabetes medications and whether adjustment is needed

Frequently asked questions

Does semaglutide affect testosterone in men? Obesity itself suppresses testosterone — adipose tissue converts testosterone to oestrogen, and chronically elevated insulin also suppresses testosterone production. Weight loss from any cause — including semaglutide — consistently improves testosterone levels. Semaglutide does not directly affect testosterone, but the weight loss it produces is beneficial for male hormone levels.

I have a pot belly but I am not otherwise overweight. Do I qualify? Central obesity — excess abdominal fat — is a qualifying factor when combined with metabolic comorbidities (pre-diabetes, hypertension, fatty liver, dyslipidaemia). If your BMI is below 27.5 but your waist circumference is above 90 cm and you have one or more of these conditions, discuss this with a ZIVOLABS doctor. The metabolic risk profile matters more than the number on the scale alone.

Will this affect my energy or ability to exercise? In the first 2–4 weeks, some patients experience mild fatigue as appetite decreases and caloric intake reduces. Beyond that initial adjustment, the majority of patients report improved energy — a direct result of weight loss, improved blood sugar regulation, and better sleep. Most men find their capacity for exercise improves meaningfully over the first 3–6 months.

I travel a lot for work. Is this manageable? Yes. Semaglutide is a once-weekly injection. ZIVOLABS consultations are online. The current pen can be stored at room temperature below 30°C for up to 28 days. It is designed to fit into a demanding professional schedule.

I am embarrassed to talk about my weight with a doctor. Is this really necessary? ZIVOLABS doctors are metabolic specialists who treat overweight and obesity every day. There is no judgment. The consultation is private, conducted from home, and focused on your health — not your lifestyle choices. The health assessment can be completed before you speak to anyone.

The bottom line

GLP-1 medication works in men. The clinical evidence is unambiguous. The specific health conditions most common in overweight Indian men — abdominal obesity, Type 2 diabetes, fatty liver, sleep apnoea, hypertension — are exactly the conditions it addresses most effectively.

The barrier is not medical. It is cultural. And an online consultation is a lower threshold than walking into a clinic.

[Start your health assessment →]

This article is for informational purposes only and does not constitute medical advice. Semaglutide is a prescription medication. Always consult a qualified doctor before starting any new treatment. Individual results may vary.